Amgen, Inc. (AMGN), Astex Pharmaceuticals, Inc. (ASTX), Pharmacyclics, Inc. (PCYC): This Week in Biotech

With the SPDR S&P Biotech Index up 35% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let’s have a look at some of the rulings, studies, and companies that made waves in the sector last week.

Perhaps no story headlined this past week more than the announcement (finally!) that Amgen, Inc. (NASDAQ:AMGN) would be purchasing Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) for $10.4 billion, or $125 a share. After multiple potential bidders dropped out of the running, only Amgen, Inc. (NASDAQ:AMGN) was left standing — and for just $5 more per share than its previous offer. To add icing on the cake to the deal, the EU approved Bayer and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)’s Stivarga on Friday for the treatment of metastatic colorectal cancer. My initial assessment of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) valued the company as high as $145 a share, thanks to strong forecasted growth from Kyprolis in treating multiple myeloma, so I’d certainly say Amgen, Inc. (NASDAQ:AMGN) is getting a pretty good deal.

Amgen, Inc. (NASDAQ:AMGN)

Shareholders in Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) aren’t complaining much, either, with shares rising by double digits after the company reported positive top-line results in a mid-stage study of SGI-110 for acute myeloid leukemia. Based on Astex Pharmaceuticals, Inc. (NASDAQ:ASTX)’s press release, of the 67 patients treated in the trial, 25% demonstrated an overall complete remission rate — nine refractory and relapsed AML patients, and eight treatment-naive patients. Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) plans to release the full details of the study in December, but in the meantime, shareholders have plenty to cheer about.

Speaking of cheering and getting the pompons out, Pharmacyclics, Inc. (NASDAQ:PCYC) announced on Thursday that the Food and Drug Administration had accepted its new drug application filing for ibrutinib, an oral B-cell malignancy drug designed to treat mantle cell lymphoma and chronic lymphocytic leukemia. Not only did the FDA accept ibrutinib, but it’ll also receive a priority review, meaning it could make it to market even faster. The acceptance of Pharmacyclics, Inc. (NASDAQ:PCYC)’ NDA triggers a $75 million milestone payment from its licensing partner Johnson & Johnson.

But, just as we did last week, we’ll end on a sour note with Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), which reported on Monday that R343, an inhaled SYK inhibitor that was in mid-stage trials to treat allergic asthma, failed to meet its primary and secondary endpoints in the study. Although Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) noted that the drug was well tolerated, the primary endpoint of a pre-defined change in pre-bronchodilator FEV1 (a measure of how much air a patient can expel from their lungs within the first second) relative to the placebo was not met. As such, R343 will be shelved and Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shareholders will be forced to chalk up another disappointing study.

The article This Week in Biotech originally appeared on Fool.com and is written by Sean Williams.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool owns shares of, and recommends Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 44 percentage points in 21 months Learn how!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!